The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10491 malaria professionals are enjoying the free benefits of MalariaWorld today

RTS

The thermostability of the RTS,S/AS01 malaria vaccine can be increased by co-lyophilizing RTS,S and AS01

June 9, 2020 - 16:05 -- Open Access
Author(s): 
Juliette Fortpied, Sylvie Collignon, Nicolas Moniotte, Frédéric Renaud, Babak Bayat and Dominique Lemoine
Reference: 
Malaria Journal 2020 19:202, 8 June 2020

Developing thermostable vaccines is a challenge for pharmaceutical companies due to the inherent instability of biological molecules in aqueous solution. The problem is even more stringent in regions subjected to high temperatures in which protective cold chain is difficult to maintain due to a lack of infrastructure. Here, a simple, cost-effective solution to increase the thermostability of the malaria candidate vaccine RTS,S/AS01 is described. This vaccine currently needs to be stored between 2 and 8  °C due to the sensitivity of liquid AS01 to higher temperatures. The strategy was to increase thermostability by co-lyophilizing the RTS,S antigen and AS01.

NOT Open Access | Case reduction and cost-effectiveness of the RTS,S/AS01 malaria vaccine alongside bed nets in Lilongwe, Malawi

May 6, 2020 - 15:39 -- NOT Open Access
Author(s): 
Bell GJ, Loop M, Emch M, et al.
Reference: 
Vaccine. 2020 Apr 30. pii: S0264-410X(20)30511-9

RTS,S/AS01, the most advanced vaccine against malaria, is now undergoing pilot implementation in Malawi, Ghana, and Kenya where an estimated 360,000 children will be vaccinated each year. In this study we evaluate RTS,S/AS01 alongside bed net use and estimate cost-effectiveness.

RTS,S vaccine: an African medical doctor raises the alarm.

February 1, 2020 - 14:57 -- Pierre Lutgen
Tags: 

 

This document was submitted to us by Jerôme Munyangi, who run the successful large scale clinical trials against malaria with Artemisia plants in Maniema, RDC.

        (Jerome Munyangi et al., Artemisia annua and Artemisia afra tea infusions vs. artesunate-amodiaquine(ASAQ) in treating Plasmodium falciparum malaria in a large scale, doubleblind, randomized clinical trialPhytomedicine, 2019, 57, 49-56)

Our association IFBV-BELHERB shares his concern for his African sisters and brothers. They should not be used as guinea pigs by Bigpharma.

 

Long-term immunogenicity and immune memory response to the hepatitis B antigen in the RTS,S/AS01E malaria vaccine in African children: a randomized trial

January 24, 2020 - 15:04 -- Open Access
Author(s): 
Valéa I, Adjei S, Agbenyega T, et al.
Reference: 
Hum Vaccin Immunother. 2020 Jan 17:1-7

RTS,S/AS01E malaria vaccine contains the hepatitis B virus surface antigen and may thus serve as a potential hepatitis B vaccine. To evaluate the impact of RTS,S/AS01E when implemented in the Expanded Program of Immunization, infants 8–12 weeks old were randomized to receive either RTS,S/AS01E or a licensed hepatitis B control vaccine (HepB), both co-administered with various combinations of the following childhood vaccines: diphtheria-tetanus-acellular pertussis-Haemophilus influenzae type b, trivalent oral poliovirus, pneumococcal non-typeable Haemophilus influenzae protein D conjugate and human rotavirus vaccine.

Safety and immunogenicity of the RTS,S/AS01 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa

January 24, 2020 - 14:40 -- Open Access
Author(s): 
Otieno L, Guerra Mendoza Y, Oneko M, et al.
Reference: 
Vaccine Volume 38, Issue 4, 22 January 2020, Pages 897-906

We assessed the safety and immunogenicity of the RTS,S/AS01 malaria vaccine in a subset of children identified as HIV-infected during a large phase III randomized controlled trial conducted in seven sub-Saharan African countries.

Subscribe to RSS - RTS